Xconomy | Boston - Business + Technology in the Exponential Economy

Related Posts

Biotech, cancer, Life Sciences

Ariad Gets $10M From Merck

Luke Timmerman 3/2/09

Cambridge, MA-based Ariad Pharmaceuticals said today that it expects to receive a $10 million milestone payment from its partner, Merck, in connection with the start of a mid-stage clinical trial of Ariad’s experimental drug for lung cancer. The company (NASDAQ: ARIA) used up $48 million of its cash reserves during 2008, and ended the year with $39.1 million left in the bank.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share:   Retweet Facebook Email

Add Your Thoughts



You will have 10 minutes to edit your post after you press publish.

Comments may be edited for clarity and length, rejected, or deleted. By clicking "Publish," you are agreeing to these Terms and Conditions.

    
Xconomy network map Seattle Boston San Diego
national life-sciences startups

Most Popular Stories

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.